Site Map
Home Page
Professional
Patient
About Neutropenia
First Cycle Neutropenic Events
Chemotherapy Regimen Risk
Proactive Risk Assessment
Facts About Neutropenia
About Neulasta
®
First Cycle Protection
Safety Information
Dosage and Administration
FAQs
Neulasta
®
Fact Sheet
Reimbursement
Reimbursement Connection
®
Professional Resources
Medical Information Connection
™
Links
Important Product Safety Information
Prescribing Information
About Low White Blood Cell Counts
Who is Most at Risk?
Understanding Your Blood Counts
How Neulasta
®
Can Help
Helping to Protect Against Infection
Questions to Ask Your Doctor
Support and Resources
Patient Assistance
ChemoCoach™ Newsletters
Information on Neutropenia and Cancer
Glossary of Terms
Important Product Safety Information
Neulasta<sup>®</sup> (pegfilgrastim) is prescribed to reduce the risk of infection (initially marked by fever) in patients with some tumors receiving strong chemotherapy that decreases the number of infection-fighting white blood cells.
<b>Important product safety information</b><br> Ruptured spleen (including fatal cases), serious allergic reactions, and a serious lung problem called acute respiratory distress syndrome have been reported. Call your doctor or seek emergency care right away if you have abdominal or shoulder tip pain, shortness of breath, trouble breathing, a fast rate of breathing, or any allergic reaction. The most common side effect of this injection is mild to moderate bone pain. If you have any questions about this information, be sure to discuss them with your doctor. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit <a href="http://www.fda.gov/medwatch" target="_blank">www.fda.gov/medwatch</a> or call 1-800-FDA-1088.
Amgen.com
|
Chemotherapy.com
© 2008 Amgen. All rights reserved.
Neulasta
®
Product Information
